Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Primary Graft Dysfunction after Lung Transplant with T-Cell Depletion

Kuan, Chieh-Hsin (2009) Primary Graft Dysfunction after Lung Transplant with T-Cell Depletion. Master's Thesis, University of Pittsburgh. (Unpublished)

[img]
Preview
PDF
Primary Text

Download (358kB) | Preview

Abstract

The objective of the study is to determine whether T cell depletion through pretreatment with either Thymoglobulin or Campath influences the incidence and severity of PGD (primary graft dysfunction) after human lung transplantation.This is a single center study, conducted between July 2000 and November 2004, and is a retrospective analysis of 206 patients. Patients received one of following forms of induction therapy: Zenapax (n=28), Thymoglobulin (n=37), Campath (n=76), or no induction (n=65) therapy. Donor and recipient demographic, operative information, and survival data were collected. Assignment of primary grading dysfunction (PGD) grading was based on the International Society for Heart and Lung Transplantation (ISHLT) grading guidelines.While baseline characteristics were similar for most variables, grafts for patients that received Campath (293±64 min) or Thymoglobulin (282±66 min) had a longer duration of ischemic time compared to the control group, no induction therapy (246±65 min). A significant difference between Campath (78.9%) and no induction (92.3%) group was observed with a p-value of 0.047 for the overall severity of PGD. In the multivariate analysis, Perfadex (p=0.009, OR=0.31), the preservation solution, remained as a protective agent on preventing recipients from severe PGD, and use of CPB (cardiopulmonary bypass) (p<<0.001, OR=4.53) was identified to be a statistically significant risk factor for development of grade 3 PGD. There was improved early oxygenation and improved one year survival in patients that received Campath compared to the control group.The combined use of Campath as induction therapy and the graft preservation solution of Perfadex seem to be protective against the development of grade 3 PGD as their roles on defending cumulative incidence of PGD were hindered. The use of CPB was an independent risk factor to the development of grade 3 PGD. These results suggest that the development of PGD after human lung transplantation is mainly due to intrinsic immune or non-immune mechanisms, further study will be necessary to unravel the role of T cells, and it will have significant impact on public health relevance application.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: University of Pittsburgh ETD
Status: Unpublished
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Kuan, Chieh-Hsinkuanch16@hotmail.com
ETD Committee:
TitleMemberEmail AddressPitt UsernameORCID
Committee ChairDay, Richardrdfac@pitt.eduRDFAC
Committee MemberYouk, Adaayouk@pitt.eduAYOUK
Committee MemberKaczorowski, Davidkaczorowskidj@upmc.edu
Committee MemberMcCurry, Kenneth Rmccurrykr@upmc.edu
Date: 29 January 2009
Date Type: Completion
Defense Date: 28 July 2008
Approval Date: 29 January 2009
Submission Date: 11 April 2008
Access Restriction: 5 year -- Restrict access to University of Pittsburgh for a period of 5 years.
Institution: University of Pittsburgh
Schools and Programs: Graduate School of Public Health > Biostatistics
Degree: MS - Master of Science
Thesis Type: Master's Thesis
Refereed: Yes
Uncontrolled Keywords: PGD; Primary Graft Dysfunction; Lung Transplant; T-Cell Depletion
Other ID: http://etd.library.pitt.edu/ETD/available/etd-04112008-155216/, etd-04112008-155216
Date Deposited: 10 Nov 2011 19:35
Last Modified: 15 Nov 2016 13:39
URI: http://d-scholarship.pitt.edu/id/eprint/7013

Metrics

Monthly Views for the past 3 years

Plum Analytics


Actions (login required)

View Item View Item